Please assess the completion status of the following clinical trial:

Trial Title: Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Patients diagnosed with cancer and experiencing chronic neuropathic pain syndrome~  * Pain syndrome diagnosed by the investigator~ * Pain syndrome related to the effects of cancer or its treatment (i.e., chemotherapy, radiotherapy, and surgery)~ * Meets 1 of the following criteria:~    * Need to be started on strong opioids~   * Require an increase in opioid dose and are currently taking ≤ 75 mg of total daily dose of oral morphine equivalent~* Experiencing pain for ≥ 4 weeks with an average pain score of ≥ 4 or a worst pain score of ≥ 5 (using the 0-10 Brief Pain Inventory Scale) during the past 24 hours~* Requires strong opioids to control pain and is using an oral morphine-equivalent dose of 0-75 mg per day, on average, including breakthrough analgesia, within the past 3 full calendar days~* Mixed pain syndrome allowed provided the neuropathic component is the predominant pain~* Meets 1 of the following criteria:~  * Receiving concurrent chemotherapy but the chronic neuropathic pain is not related to this treatment and is not expected to improve or worsen because of this therapy~ * Received prior chemotherapy but discontinued treatment, has not received chemotherapy within the past 7 days, and no further chemotherapy is planned~ * No prior chemotherapy~PATIENT CHARACTERISTICS:~* Karnofsky performance status 40-100%~* ALT and AST ≤ 3 times upper limit of normal (ULN)~* Creatinine ≤ 2 times ULN~* No other known laboratory abnormality that, in the investigator's opinion, would contraindicate study participation~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Mini-Mental State Examination score ≥ 25/30~* Able to speak, read, and write in either English or French~* Willing to complete study diary and questionnaires~* Available for study treatment and follow up (i.e., within reasonable geographical limits of the participating center)~* Able to swallow and tolerate oral medications~* Patients with prior exposure to methadone hydrochloride must be able to tolerate it~* No intractable nausea and vomiting~* No presence or history of unstable disease or condition that would, in the investigator's opinion, preclude patient participation in study treatment, such as:~  * Head injury~ * Increased intracranial pressure~ * Uncontrolled seizures~ * Uncontrolled asthma~ * Decompensated chronic obstructive pulmonary disease~ * Untreated prostate hypertrophy~ * Acute abdominal conditions~ * Untreated hyperthyroidism and Addison disease~ * Increased cerebrospinal fluid pressure~ * Urethral stricture~ * Severe cardiac arrhythmias (especially prolonged QT interval)~ * Symptomatic hypotension~ * Toxic psychosis~ * Cor pulmonale~ * Sleep apnea~ * Severe obesity~ * Kyphoscoliosis~ * Myxedema~ * Central nervous system depression~ * Coma~* No history of significant alcohol, analgesic, or narcotic substance abuse within the past 6 months~* Able physically and mentally to answer questions and comply with study treatment~* No patient who lives alone and cannot access at least 1 caregiver who can monitor on a daily basis at home~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 3 weeks since prior radiopharmaceutical treatment or radiotherapy~* Concurrent co-analgesics and medications that can affect methadone hydrochloride metabolism allowed provided patients have been on a stable dose for the past 3-5 days and ≥ 5 half lives have passed since any change in dose~* Not scheduled to start chemotherapy during the study treatment~* Not planning on starting or discontinuing medication associated with modified methadone hydrochloride clearance during study treatment~* No concurrent therapeutic procedure that is likely to influence pain intensity during the study period~* No concurrent other opioid medications~* No other concurrent methadone hydrochloride

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Methadone (Type: ACTIVE_COMPARATOR): Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)
- Arm B: Methadone (Type: ACTIVE_COMPARATOR): Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)

Based on this trial design, predict the completion outcome and termination type (if applicable).